{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:14:17Z","timestamp":1792282457800,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalimaging.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clinimag.2017.12.014","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T19:48:54Z","timestamp":1515527334000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Multimodality imaging of endocrine immune related adverse events: a primer for radiologists"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-1284","authenticated-orcid":false,"given":"Francesco","family":"Alessandrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinimag.2017.12.014_bb0005","author":"U.S. Food and Drug Administration"},{"issue":"8","key":"10.1016\/j.clinimag.2017.12.014_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clinimag.2017.12.014_bb0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clinimag.2017.12.014_bb0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.clinimag.2017.12.014_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","article-title":"Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials","volume":"92","author":"Kudo","year":"2017","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.clinimag.2017.12.014_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.clinimag.2017.12.014_bb0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0055","author":"National Cancer Institute"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"1","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side-effects of immune checkpoint inhibitors","volume":"28","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinimag.2017.12.014_bb0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"Radiographics"},{"issue":"10","key":"10.1016\/j.clinimag.2017.12.014_bb0085","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune mediated adverse events of anticytotoxic T lymphocyte associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0095","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.clinimag.2017.12.014_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0110","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","author":"Barroso-Sousa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clinimag.2017.12.014_bb0115","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9948","key":"10.1016\/j.clinimag.2017.12.014_bb0120","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0125","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"2","key":"10.1016\/j.clinimag.2017.12.014_bb0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.clinimag.2017.12.014_bb0140","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.clinimag.2017.12.014_bb0145","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3348\/kjr.2017.18.1.42","article-title":"Immune-checkpoint inhibitors in the era of precision medicine: what radiologists should know","volume":"18","author":"Braschi-Amirfarzan","year":"2017","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0155","series-title":"Hypophysitis associated with immunomodulatory therapies","author":"Vaz","year":"2016"},{"issue":"5","key":"10.1016\/j.clinimag.2017.12.014_bb0160","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2016.6611","article-title":"Headache in the setting of immunotherapy treatment for metastatic melanoma","volume":"3","author":"Comstock","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0165","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.clinimag.2017.12.014_bb0170","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with Ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy","volume":"121","author":"Lammert","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1148\/radiology.195.1.7892490","article-title":"Lymphocytic adenohypophysitis: contrast-enhanced MR imaging in five cases","volume":"195","author":"Ahmadi","year":"1995","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.clinimag.2017.12.014_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.clinimag.2017.12.014_bb0205","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-011-0197-2","article-title":"Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management","volume":"6","author":"Brown","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"3","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinimag.2017.12.014_bb0220","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clinimag.2017.12.014_bb0225","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clinimag.2017.12.014_bb0230","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"De Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"15 suppl","key":"10.1016\/j.clinimag.2017.12.014_bb0235","doi-asserted-by":"crossref","first-page":"4010a","DOI":"10.1200\/jco.2015.33.15_suppl.4010","article-title":"Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028","volume":"33","author":"Doi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0240","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"10.1016\/j.clinimag.2017.12.014_bb0245","doi-asserted-by":"crossref","first-page":"9055a","DOI":"10.1200\/jco.2015.33.15_suppl.9055","article-title":"Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI)","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clinimag.2017.12.014_bb0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/17512433.2016.1133289","article-title":"Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer","volume":"9","author":"Rossi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0255","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0260","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms","author":"Delivanis","year":"2017","journal-title":"Clin Endocrinol Metab"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1346-8138.13028","article-title":"Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab","volume":"43","author":"Narita","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-213692","article-title":"Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung","author":"Verma","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0280","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2214\/AJR.09.2459","article-title":"Hashimoto thyroiditis: part 1, sonographic analysis of the nodular form of Hashimoto thyroiditis","volume":"195","author":"Anderson","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0285","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/COC.0b013e31829d1d09","article-title":"Metastasis to the thyroid gland: report of a large series from the Mayo Clinic","volume":"38","author":"Hegerova","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"9935","key":"10.1016\/j.clinimag.2017.12.014_bb0290","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clinimag.2017.12.014_bb0295","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nuc Med"},{"issue":"3","key":"10.1016\/j.clinimag.2017.12.014_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0305","first-page":"0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"16","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"10.1016\/j.clinimag.2017.12.014_bb0310","doi-asserted-by":"crossref","first-page":"22584","DOI":"10.3390\/ijms160922584","article-title":"Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus","volume":"16","author":"Perri","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0315","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"9","key":"10.1016\/j.clinimag.2017.12.014_bb0320","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2337\/dc15-0889","article-title":"Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0325","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0330","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0335","unstructured":"Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. Up to date Atkins MB (Ed). Accessed 21 July 2017."},{"key":"10.1016\/j.clinimag.2017.12.014_bb0340","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clinimag.2017.12.014_bb0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CMR.0000000000000273","article-title":"A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy","volume":"26","author":"Kottschade","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clinimag.2017.12.014_bb0350","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","article-title":"Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma","volume":"105","author":"Munakata","year":"2017","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.clinimag.2017.12.014_bb0355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"239","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.clinimag.2017.12.014_bb0365","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.clinimag.2017.12.014_bb0370","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.clinimag.2017.12.014_bb0375","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00261-017-1050-6","article-title":"Biliary and pancreatic complications of molecular targeted therapies in cancer imaging","volume":"42","author":"Alessandrino","year":"2017","journal-title":"Abdom Radiol"},{"issue":"8","key":"10.1016\/j.clinimag.2017.12.014_bb0380","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.clinimag.2017.12.014_bb0385","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707117302644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707117302644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T01:56:04Z","timestamp":1660269364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707117302644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":77,"alternative-id":["S0899707117302644"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2017.12.014","relation":{},"ISSN":["0899-7071"],"issn-type":[{"value":"0899-7071","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodality imaging of endocrine immune related adverse events: a primer for radiologists","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2017.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}